Document:

Exhibit
10.4

 

SECURITIES
PURCHASE AGREEMENT

 

THIS
SECURITIES PURCHASE AGREEMENT (the “Agreement”) is effective as of the 5th day of June 2020 (the “Closing
Date”), by and between, OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and
each investor identified on the signature pages to this Agreement (each, an “Investor”).

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements
of Section 5 of the Securities Act contained in Section 4(a)(2) thereof and/or Rule 506(b) thereunder, the Company desires to
issue and sell to each Investor, and each Investor, severally and not jointly, desires to purchase from the Company, securities
of the Company as more fully described in this Agreement;

 

WHEREAS,
the Company has authorized a new series of Convertible Preferred Stock of the Company designated as Series C-2 Convertible Preferred
Stock, $0.0001 par value (the “Series C-2”), the terms of which are set forth in the Certificate of Designations
for such series of Series C-2 Preferred Stock (the “Certificate of Designations”) in the form attached hereto
as Exhibit A;

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree
as follows:

 

1.
Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with
the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Investors agree to purchase
an aggregate of 3,523.7533 shares of Series C-2. The Investors shall deliver to the Company, via wire transfer of immediately
available funds equal to the Purchaser’s subscription amount (the “Subscription Amount”) as set forth
on the signature pages hereto executed by the Investors, and the Company shall deliver to the Investors the shares of Series C-2.
Upon satisfaction of the covenants and conditions set forth herein, the Closing shall occur at the offices of K&L Gates LLP,
Company counsel or such other location as the parties shall mutually agree. At the closing of the sale of the Series C-2 (the
“Closing”):

 

1.1.
Delivery of Securities. On the Closing Date, the Company shall issue the Series C-2 to each Investor (or its designees);
provided that each Investor has complied with its obligations in this Section 1. Promptly after the Closing Date, the Company
shall deliver a certificate evidencing the Series C-2 to each Investor. On the Closing Date, each Investor shall be deemed for
all corporate purposes to have become the holder of record of the Series C-2 and shall have the right to convert the Series C-2,
irrespective of the date the Company delivers the certificate evidencing the Series C-2 to each Investor.

 

1.2.
Further Assurances. The Company and each Investor shall execute and/or deliver such other documents and agreements as are
customary and reasonably necessary to effectuate the Closing.

 

    	 	 	 

    	 	 	 

    

 

1.3.
Representations and Warranties True at Closing. It shall be a condition to the obligation of the Investor on the one hand
and Company on the other hand, to consummate the transactions contemplated hereunder that the other party’s representations
and warranties contained herein are true and correct on the Closing Date with the same effect as though made on such date, unless
waived in writing by the party to whom such representations and warranties are made.

 

1.4.
Deliveries. At or before the Closing, each Investor shall deliver or cause to be delivered to the Company, (i) the Investor’s
Subscription Amount by wire transfer to the Company and (ii) the executed Agreement.

 

2.
Representations and Warranties of the Company. The Company hereby represents and warrants to each Investor that:

 

2.1.
Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Nevada. The Company is duly qualified to transact business and is in good standing in
each jurisdiction in which the failure to so qualify would have a Material Adverse Effect (as defined below) on its business or
properties. As used in this Agreement, “Material Adverse Effect” means any material adverse effect on the business,
properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company
and its Subsidiaries, individually or taken as a whole, or on the transactions contemplated hereby or by the agreements and instruments
to be entered into in connection herewith, or on the authority or ability of the Company to perform its obligations under this
Agreement.

 

2.2.
Authorization. All corporate action on the part of the Company, its officers, directors and stockholders necessary for
the authorization, execution and delivery of this Agreement and the performance of all obligations of the Company hereunder and
thereunder, and the authorization of the issuance of the Series C-2, have been taken on or prior to the date hereof. The Certificate
of Designations has been validly filed with the Secretary of State of Nevada and, as of the date hereof and the Closing Date,
remains in full force and effect.

 

2.3.
Valid Issuance of the Series C-2. The Series C-2 shares when issued and delivered in accordance with the terms of this
Agreement, for the consideration expressed herein, and the Common Stock when issued in accordance with the terms of the Certificate
of Designations, for the consideration expressed therein, will be duly and validly issued, fully paid and non-assessable. Upon
conversion of the Series C-2, the Common Stock shall be freely tradable and may be sold under Rule 144 promulgated under the Securities
Act (“Rule 144”) subject to the requirements of Rule 144(i). If on the Closing Date, any Investor does not
already have such amount of shares reserved, the Company shall, within two business days after the Company files an amendment
of its Articles of Incorporation to increase the number of shares of Common Stock it is authorized to issue with the Secretary
of State of the State of Nevada, the Company shall reserve from its duly authorized capital stock not less than 125% of the maximum
number of shares of Common Stock issuable upon conversion of such Investor’s Series C-2 (assuming for purposes hereof that
such Series C-2 are convertible at the initial Conversion Price and any such reservation shall not take into account any limitations
on the conversion of the Series C-2 set forth herein).

 

    	 	2	 

    	 	 	 

    

 

2.4.
Compliance With Laws. The Company has not violated any law or any governmental regulation or requirement which violation
has had or would reasonably be expected to have a Material Adverse Effect, and the Company has not received written notice of
any such violation.

 

2.5.
Consents; Waivers. No consent, waiver, approval or authority of any nature, or other formal action, by any individual,
a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government
or any department or agency thereof (each, a “Person”), not already obtained, is required in connection with
the execution and delivery of this Agreement by the Company or the consummation by the Company of the transactions provided for
herein and therein.

 

2.6.
Acknowledgment Regarding Investor’s Purchase of Series C-2. The Company acknowledges and agrees that each Investor
is acting solely for itself and not any other Investor in the capacity of arm’s length purchaser with respect to this Agreement
and the transactions contemplated hereby and that each Investor is not (i) an officer or director of the Company, (ii) an “affiliate”
of the Company (as defined in Rule 144 promulgated under the Securities Act), or (iii) to the knowledge of the Company, a “beneficial
owner” of more than 9.9% of the shares of Common Stock (as defined for purposes of Rule 13d-3 under the Exchange Act). The
Company further acknowledges that each Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to this Agreement and the transactions contemplated hereby, and any advice given by the Investor or any
of its representatives or agents in connection with this Agreement and the transactions contemplated hereby and thereby is merely
incidental to the Investor’s acceptance of the Series C-2. The Company further represents to the Investor that the Company’s
decision to enter into this Agreement has been based solely on the independent evaluation by the Company and its representatives.

 

2.7.
Absence of Litigation. To the knowledge of the Company, there is no action, suit, proceeding, inquiry or investigation
before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of
the Company, threatened against or affecting the Company, the Common Stock, the Series C-2 or any of the Company’s officers
or directors in their capacities as such.

 

2.8.
Validity; Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf
of the Company and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in
accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the
enforcement of applicable creditors’ rights and remedies. The execution, delivery and performance by the Company of this
Agreement and the consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation
of the organizational documents of the Company or (ii) conflict with, or constitute a default (or an event which with notice or
lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Company is a party or by which it is bound, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including federal and state securities or “Blue Sky” laws)
applicable to the Company, except in the case of clause (ii) above, for such conflicts, defaults or rights which would not, individually
or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

    	 	3	 

    	 	 	 

    

 

2.9.
No General Solicitation. Neither the Company, nor any of its Subsidiaries or affiliates, nor any Person acting on its or
their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection
with the offer or sale of the Series C-2.

 

2.10.
Private Placement. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3,
no registration under the Securities Act is required for the offer and sale of the Notes, the Shares upon conversion thereof,
the Warrants or the Warrant Shares issuable upon exercise thereof by the Company to the Purchaser as contemplated hereby.

 

3.
Representations and Warranties of the Investor. Each Investor hereby represents, warrants and covenants that:

 

3.1.
Authorization. The Investor has full power and authority to enter into this Agreement, to perform its obligations hereunder
and to consummate the transactions contemplated hereby and has taken all action necessary to authorize the execution and delivery
of this Agreement, the performance of its obligations hereunder and the consummation of the transactions contemplated hereby.

 

3.2.
No Public Sale or Distribution. The Investor is acquiring the Series C-2 in the ordinary course of its business, for its
own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation
of applicable securities laws; provided, however, by making the representations herein, the Investor does not agree, or make any
representation or warranty, to hold any of the Series C-2 for any minimum or other specific term and reserves the right to dispose
of the Series C-2 at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act. The
Investor does not presently have any agreement or understanding, directly or indirectly, with any Person to distribute any of
the Series C-2.

 

3.3.
Accredited Investor Status. At the time the Investor was offered the Series C-2, it was, and as of the date hereof it is,
and at Closing it will be, an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8)
under the 1933 Act.

 

3.4.
Experience of Investor. The Investor, has such knowledge, sophistication and experience in business and financial matters
so as to be capable of evaluating the merits and risks of the investment in the Series C-2, and has so evaluated the merits and
risks of such investment. The Investor is able to bear the economic risk of an investment in the Series C-2 and is able to afford
a complete loss of such investment. The Investor acknowledges and agrees that the Company has not made any representations or
warranties with respect to the Series C-2 or the transactions contemplated hereby other than those specifically set forth in Section
2, and the Investor acknowledges and agrees that it has relied solely upon the representations and warranties contained in Section
2 in determining whether to enter into this Agreement and to consummate the transactions contemplated hereby and thereby.

 

    	 	4	 

    	 	 	 

    

 

3.5.
Reliance on Exemptions. The Investor understands that the Series C-2 are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
in part upon the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Investor set forth herein in order to determine the availability of such exemptions
and the eligibility of the Investor to acquire the Series C-2.

 

3.6.
Information. The Investor and its advisors, if any, have been furnished with all materials relating to the business, finances
and operations of the Company and materials relating to the offer and sale of the Series C-2 which have been requested by the
Investor. The Investor and its advisors, if any, have been afforded the opportunity to ask questions of the Company and has received
answers, satisfactory in all respect to the Investor, to all such questions. The Investor understands that its investment in the
Series C-2 involves a high degree of risk. The Investor has sought such accounting, legal and tax advice as it has considered
necessary to make an informed investment decision with respect to its acquisition of the Series C-2, and the Investor acknowledges
and agrees that the Company has not provided to the Investor any accounting, legal, tax or other advice in respect of the transactions
contemplated by the this Agreement, including the offer, purchase and sale of the Series C-2.

 

3.7.
No Governmental Review. The Investor understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Series C-2 or the fairness or suitability
of the investment in the Series C-2 nor have such authorities passed upon or endorsed the merits of the offering of the Series
C-2.

 

3.8.
Transfer or Resale. The Investor understands that: (i) the Series C-2 have not been and are not being registered under
the 1933 Act or any state or other securities laws, and may not be offered for sale, sold, assigned or transferred unless (A)
subsequently registered thereunder, or (B) the Investor shall have delivered to the Company (if requested by the Company) an opinion
of counsel to the Investor, in a form and substance reasonably acceptable to the Company, to the effect that such Series C-2 to
be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C)
the Investor provides the Company with reasonable assurance that, at the time of any sale of such sale of transfer, such Series
C-2 may be legally sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act (or a successor
rule thereto); (ii) any sale of the Series C-2 made in reliance on Rule 144 may be made only in accordance with the terms of Rule
144, and further, if Rule 144 is not applicable, any resale of the Series C-2 under circumstances in which the seller (or the
Person (as defined below) through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933
Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC promulgated thereunder;
and (iii) neither the Company nor any other Person is under any obligation to register the Series C-2 under the 1933 Act or any
state securities laws or to comply with the terms and conditions of any exemption thereunder.

 

    	 	5	 

    	 	 	 

    

 

3.9.
Validity; Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf
of the Investor and shall constitute the legal, valid and binding obligations of the Investor enforceable against the Investor
in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally,
the enforcement of applicable creditors’ rights and remedies.

 

3.10.
General Solicitation. The Investor is not purchasing the Series C-2 as a result of any advertisement, article, notice or
other communication regarding the Series C-2 published in any newspaper, magazine or similar media or broadcast over television
or radio or presented at any seminar.

 

4.
Additional Covenants.

 

4.1.
Disclosure. The Company shall, on or before 8:30 a.m., Eastern time, on the fourth business day after the date of this
Agreement, file with the Securities and Exchange Commission a Current Report on Form 8-K disclosing all material terms of the
transactions contemplated hereby and attaching the form of this Agreement and the Certificate of Designations as exhibits thereto
(collectively with all exhibits attached thereto, the “8-K Filing”). From and after the issuance of the 8-K
Filing, no Investor shall be in possession of any material, nonpublic information received from the Company or any of its subsidiaries
or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the 8-K Filing. The
Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, provide any Investor with
any material, nonpublic information regarding the Company from and after the filing of the 8-K Filing without the express written
consent of such Investor. To the extent that the Company delivers any material, non-public information to an Investor without
such Investor’s express prior written consent, the Company hereby covenants and agrees that such Investor shall not have
any duty of confidentiality to the Company, any of its subsidiaries or any of their respective officers, directors, employees,
affiliates or agents with respect to, or a duty to the Company, any of its subsidiaries or any of their respective officers, directors,
employees, affiliates or agents or not to trade on the basis of, such material, non-public information. The Company shall not
disclose the name of any Investor in any filing, announcement, release or otherwise, unless such disclosure is required by law
or regulation. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all
confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries
or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Investor or any of its
affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that
each Investor will rely on the foregoing representations in effecting transactions in securities of the Company.

 

    	 	6	 

    	 	 	 

    

 

4.2.
Blue Sky. The Company shall make all filings and reports relating to the offer and sale of Series C-2 hereby required under
applicable securities or “Blue Sky” laws of the states of the United States following the date hereof, if any.

 

4.3.
Fees and Expenses. Except as otherwise set forth above, each party to this Agreement shall pay the fees and expenses of
its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement.

 

4.4.
Issuance of Unrestricted Common Stock. The Company agrees to take all actions, including, without limitation, the issuance
by its legal counsel, or any legal counsel reasonably acceptable to the Company, of any legal opinions, to issue unrestricted
Common Stock pursuant to Rule 144 in the connection of any sale of Common Stock issued upon conversion of Series C-2 by any Investor
in compliance with Rule 144; provided that each such investor provides customary representation letters and all other such documentation
as required by counsel to the Company to issue a legal opinion.

 

4.5.
Commitment Fee. In consideration for Cavalry Fund’s and Lincoln Park Capital’s coordination and arrangement
of this Agreement and the other transactions contemplated to take place on the Closing Date, the Company shall issue each a warrant,
in the form set forth as Exhibit B hereto, in the amount of 133,333,333 shares to Cavalry Fund and 66,666,667 shares to
Lincoln Park.

 

5.
Miscellaneous

 

5.1.
Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the parties hereto and the respective successors and assigns of the parties. Nothing in this
Agreement, express or implied, is intended to confer upon any party, other than the parties hereto or their respective successors
and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.

 

5.2.
Governing Law; Exclusive Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law
or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state or federal courts sitting in New York County, New York, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT
IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING
OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    	 	7	 

    	 	 	 

    

 

5.3.
Notices. All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing,
and shall be sufficiently given if delivered to the addressees in person, by FedEx or similar overnight next business day delivery,
or by email followed by overnight next business day delivery, to the address as provided for on the signature page to this Agreement.

 

5.4.
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may
be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent
of the Company and the Investor.

 

5.5.
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision
shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded
and shall be enforceable in accordance with its terms so long as this Agreement as so modified continues to express, without material
change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability
of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties
or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in
good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect
of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

5.6.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.

 

5.7.
Survival. Sections 4 and 5 of this Agreement shall survive the Closing and delivery of the Series C-2.

 

[SIGNATURES
ON THE FOLLOWING PAGE]

 

    	 	8	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	OncBioMune
    Pharmaceuticals, INC.
	 	 	 
	 	By:	/s/
                                         Andrew Kucharchuk                   

	 	Name:
    	Andrew
    Kucharchuk
	 	Title:
    	Chief
    Executive Officer
	 	 
	 	Address
    for Notices:
	 	 
	 	11441
        Industriplex Blvd, Suite 190

        Baton
        Rouge, LA 70809

        Email:
        akucha1.obmp@gmail.com

 

    	 	 	 

    	 	 	 

    

 

INVESTOR
SIGNATURE PAGES TO OBMP SECURITIES PURCHASE AGREEMENT

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

Name of Investor: Cavalry Fund I LP

 

Signature of Authorized Signatory of Investor:     /s/
Thomas Walsh                                               

 

Name of Authorized Signatory:    Thomas
Walsh                                                

 

Title of Authorized Signatory:       Manager                                             

 

Email Address of Authorized Signatory:                                                    

 

Facsimile Number of Authorized Signatory:                                                    

 

Address for Notice to Investor: 61 Kinderkamack
Rd., Woodcliff Lake, NJ 07677

 

Address for Delivery of Securities to Investor
(if not same as address for notice):

Subscription Amount: $262,500

 

Number of Shares to be Issued: 860.4514 shares of Series C-2

 

    	 	 	 

    	 	 	 

    

 

INVESTOR
SIGNATURE PAGES TO OBMP SECURITIES PURCHASE AGREEMENT

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

Name of Investor: Lincoln Park Capital Fund,
LLC

By: Lincoln Park Capital,
LLC

By: Rockledge Capital
Corporation

 

Signature of Authorized Signatory of Investor:     /s/
Joshua Scheinfeld                                               

 

Name of Authorized Signatory:          Joshua
Scheinfeld                                           

 

Title of Authorized Signatory:         President                                           

 

Email Address of Authorized Signatory:                                                    

 

Facsimile Number of Authorized Signatory:                                                    

 

Address for Notice to Investor: 440 N.
Wells St., Suite 410, Chicago, IL 60654

 

Address for Delivery of Securities to Investor
(if not same as address for notice):

Subscription Amount: $812,500

 

Number of Shares to be Issued: 2,663.3019 shares of Series C-2Exhibit 10.5

 

SEPARATION
AGREEMENT

AND
GENERAL RELEASE OF CLAIMS

 

This
Separation Agreement and General Release of Claims (“Agreement”) is entered into by Andrew Kucharchuk (hereinafter
referred to as “you” or “your”) and OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”).
In consideration of the mutual promises set forth below, the parties agree as follows:

 

1.
Separation of Employment. In accordance with your February 2, 2016 employment agreement (the “Employment Agreement”),
you tendered your resignation as Chief Executive Officer, President and Chief Financial Officer (“CEO/CFO”) pursuant
to Section 7(a)(iv), and the Company agreed to waive the contractual notice period and make the resignation effective June 5,
2020 (“Separation Date”). The Company will pay you all wages earned in accordance with the Company’s policies
and applicable law, through your Separation Date, including your $59,990 in back pay. The Company will also repay you the $22,012
you advanced to the Company to pay Company operating expenses. Any unused paid time off (“PTO”) earned and accrued
up to the Separation Date shall be forfeited. You will receive the amounts referenced in this Section 1 regardless of whether
you sign this Agreement.

 

2.
As provided in Section 3 below, the Company will provide you with financial benefits and other consideration in return for your
execution of this Agreement, which will fully and finally resolve any and all matters between Employer and Employee. By entering
into this Agreement, the Company does not admit any underlying liability to you. The Company is not entering into this Agreement
because of any wrongful acts of any kind.

 

3.
Severance Pay. As consideration for your execution of this Agreement, including the release of claims, the Company
will (i) pay you Two Thousand Nine Hundred and Ninety-Eight Dollars ($2,998.00) in cash and (ii) issue you on the Separation Date
Two Hundred Forty-One (241) shares of the Company’s Series D-2 Preferred Stock (collectively, the “Severance”).
You acknowledge and agree that (a) the Company is not obligated to provide you with the consideration provided in this Section
3, except under this Agreement, (b) the Company’s obligations set forth in this Section 3 provide adequate consideration
for your covenants, waiver, and release in this Agreement, and (c) your entitlement to earn and retain the Severance Pay is conditioned
on your full compliance with this Agreement and any other obligations you have to the Company. You further acknowledge and agree
that, upon receipt of the Severance and all other payments referred to in Section 1 above, you will have received all compensation
you earned while employed by the Company and that no additional compensation is owed whatsoever.

 

4.
Benefits. Upon separation, you will be provided, as required by law, notification as to your right to continue health,
vision, and dental insurance coverage under the provisions of the Consolidated Budget Reconciliation Act of 1985 (“COBRA”)
for you and any eligible dependents, if applicable. Except as specifically set forth in this Agreement, your right to, and participation
in, all employee benefit plans of the Company terminated as of the Separation Date in accordance with the specific terms of each
plan. If you timely elect continued coverage under the provisions of the Consolidated Budget Reconciliation Act of 1985 (“COBRA”),
the Company will pay your COBRA premiums necessary to continue your medical, dental and vision coverage (including coverage for
eligible dependents, if applicable) (“COBRA Premiums”) through the period (“COBRA Premium Period”) starting
on June 1, 2020 and ending on the earliest to occur: (i) November 30, 2020; (ii) the date you and your eligible dependents, if
applicable, become eligible for group health insurance coverage through a new employer; or (iii) the date you cease to be eligible
for COBRA continuation coverage for any reason, including plan termination. In the event you become covered under another employer’s
health plan or otherwise ceases to be eligible for COBRA during the COBRA Premium Period, you agree that you must notify the Company
of such event. No COBRA Premiums shall be made if you revoke this Agreement.

 

    	 	 	 

    	 

    

 

5.
Confidentiality, Non-Solicitation and Non-Compete. Section 10 of your Employment Agreement shall survive termination
of your Employment Agreement and this Agreement, and your obligation to fully comply with the terms and conditions contained therein
shall remain in full force and effect through Separation Date, and for a period of one year thereafter.

 

6.
General Release. On behalf of yourself, your marital community, heirs, representatives, executors, administrators,
successors, assigns, and any person claiming any interest in your employment or employment related compensation or benefits, you
hereby waive, release, acquit, and forever discharge the Company and the other Released Parties (as defined below) from any and
all claims, charges, complaints and causes of action, of whatever nature, that exist or may exist on your behalf against the Released
Parties up to and including the date you sign this Agreement (collectively “Released Claims”). This release is comprehensive
and Released Claims include all claims (including claims to costs or attorneys’ fees), damages, causes of action, and disputes
of any kind whatsoever, whether known or unknown, anticipated or unanticipated, contingent, or otherwise, occurring or that could
be alleged to have occurred before the execution of this Agreement. The Released Claims include, but are not limited to, any and
all claims based on contract, wages, hours, wrongful termination, wrongful termination in violation of public policy, discrimination,
harassment, retaliation, defamation, fraud, and any other tort or personal injury claims, and any and all claims arising under
any federal, state, local, foreign or other governmental statute, law or regulation relating to employment or otherwise, including
but not limited to the following: (a) the Employee Retirement Income Security Act; (b) Title VII of the Civil Rights Act of 1964;
(c) Sections 1981 and 1983 of the Civil Rights Act of 1866; (d) Sections 1981 through 1988 of Title 42 of the United States Code;
(e) the Age Discrimination in Employment Act; (f) the Equal Pay Act; (g) the Worker Adjustment Retraining and Notification Act;
(h) the Immigration Reform and Control Act; (i) the Americans with Disabilities Act, and Sections 503 and 504 of the Rehabilitation
Act of 1973; (j) the Family and Medical Leave Act; (k) the Consolidated Omnibus Reconciliation Act; (l) the Occupational Safety
and Health Act; (m) the Fair Credit Reporting Act; (n) the Vietnam Era Veterans Readjustment Assistance Act; (o) the Sarbanes-Oxley
Act of 2002; (p) the Dodd-Frank Wall Street Reform and Consumer Protection Act; (q) the Genetic Information Nondiscrimination
Act; (r) claims under Louisiana’s Worker’s Compensation Anti-Retaliation Provision, La. Rev. Stat § 23:1361;
(s) any foreign, federal, state and/or local whistleblower statute, regulation, ordinance or law; (t) any foreign, federal, state
and/or local law, statute, regulation or ordinance prohibiting discrimination, retaliation and/or harassment or governing wage
or commission payment claims; (u) all amendments to such laws; and (v) any other basis for legal or equitable relief whether based
on express or implied contract, tort, statute or other legal or equitable ground.

 

    	 - 2 -

     

    

 

However,
Released Claims do not include or affect (a) your rights to health and dental insurance continuation coverage under COBRA and
conversion rights under group life and disability plans, (b) claims for breach or enforcement of this Agreement, (c) claims that
arise after execution of this Agreement, (d) entitlement claims under ERISA for vested benefits arising under any applicable ERISA
plan, (e) workers’ compensation claims, or (f) any other claims that may not be released under this Agreement in accordance
with applicable law.

 

By
signing below, you acknowledge and agree that you have been paid for all salary, wages, and compensation earned through your last
day worked, and that you are not entitled to receive, and shall not claim from the Company, any compensation, payments or benefits
except for those payments and benefits that are expressly set forth in this Agreement.

 

For
the purpose of this Agreement, the term “Released Parties” means the Company, its affiliates, parents, subsidiaries,
joint ventures, and related companies and its and their present, former, and future successors and assigns, and all of its and
their present, former, and future owners, directors, officers, shareholders, employees, agents, representatives, assigns, insurers,
trustees, employee benefit programs (and the trustees, administrators, fiduciaries, and insurers of such programs), attorneys,
and all persons acting by, through, under or in concert with any of them, both individually and in their representative capacities.

 

7.
Return of Company Property. You represent and warrant that you have returned to the Company: (a) all originals and
copies of all proprietary or confidential information and trade secrets of the Company; (b) all originals and copies of customer
files; (c) all identification cards, keys, or other means of access to the Company or its facilities; and (d) any other property
of the Company in your possession, custody or control. All Company property must be returned no later than the date that you sign
this Agreement.

 

8.
Nondisparagement. You agree that you will not make, and that you will not instruct any other party to make, in any
manner (including oral, print, social media, electronic or other forms of communication), false, disparaging or derogatory remarks
about the Released Parties or refer negatively to your association with the Company or the other Released Parties. If you materially
breach this paragraph, you will return any previously provided Separation to the Company. This Section 8 is not intended to restrict
you from making disclosures as may be required or permitted by law or legal process (including in connection with a government
investigation). You understand and agree that your commitment not to defame, disparage, or impugn the Company’s reputation
constitutes a willing and voluntary waiver of your rights under the First Amendment of the United States Constitution and other
laws. However, these non-disparagement obligations, do not limit your ability to truthfully communicate with any administrative
agency including the Equal Employment Opportunity Commission (“EEOC”), Department of Labor (“DOL”), National
Labor Relations Board (“NLRB”), the Financial Industry Regulatory Authority (“FINRA”), or the U.S. Securities
and Exchange Commission (“SEC”) and comparable state or local agencies or departments whether such communication is
initiated by you or in response to the government.

 

    	 - 3 -

     

    

 

9.
Notice of Immunity Under the Defend Trade Secrets Act of 2016 (“DTSA”). Notwithstanding any other provision
of this Agreement or in your Employment Agreement: You will not be held criminally or civilly liable under any federal or state
trade secret law for any disclosure of a trade secret that is made: (a) in confidence to a federal, state, or local government
official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected
violation of law; or (b) in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If you file
a lawsuit for retaliation by Company for reporting a suspected violation of law, you may disclose Company’s trade secrets
to your attorney and use the trade secret information in the court proceeding if you: (a) file any document containing the trade
secret under seal; and (b) do not disclose the trade secret, except pursuant to court order.

 

10.
Non-Filing of Complaint or Charges. You represent and warrant that you have not filed any lawsuits, complaints,
or charges based on any Released Claims, except as listed below your signature. If no lawsuits, complaints, or charges are shown
below your signature, none have been filed. You understand that nothing in this Agreement prevents you from filing or prosecuting
a charge with any administrative agency (such as EEOC, NLRB, DOL, SEC or FINRA) with respect to any such claim or from participating
in an investigation or proceeding conducted by the EEOC, DOL, NLRB, SEC, FINRA or another administrative agency. You further understand
and agree that you will not seek and are hereby waiving any claim for personal damages and/or other personal relief. You agree
to cause the withdrawal or dismissal with prejudice of any claim you have purported to waive in this Agreement. If you are ever
awarded or recover any amount as to a claim you have purported to waive in this Agreement (other than under the Age Discrimination
in Employment Act if you are lawfully allowed to pursue such a claim), you agree that the amount of any award or recovery will
be reduced by ninety percent of the amounts you were paid under this Agreement, with the setoff being appropriately adjusted for
your return of any such amounts. To the extent such a setoff is not effected, you promise to pay, or assign your right to receive,
the amount that should have been set-off to the Company. You represent and warrant that you are the sole owner of any and all
Released Claims that you may have, and that you have not assigned or otherwise transferred your right or interest in any Released
Claim. To the extent permitted by law, you hereby assign to the Company any claims you may have against the Company that cannot
be legally waived here.

 

11.
Notice and Right to Consider and Revoke. You are advised to consult and review this Agreement with an attorney before
executing this Agreement. In any event, you should thoroughly review and understand the effect of this Agreement, including the
release of claims, before taking action upon it. You have twenty-one (21) days from the date you receive this Agreement to complete
your review and return the signed Agreement to the Company. You acknowledge that, if you sign this Agreement prior to the expiration
of the 21-day period, you did so voluntarily and of your own free will and choice. To accept, you must execute and deliver the
Agreement to Company’s Board of Directors, either by certified U.S. Mail to OncBioMune Pharmaceuticals, Inc., 8000 Innovation
Park Dr., Baton Rouge, LA 70820, or by email to corporate@oncbiomune.com with the signed original to follow immediately via certified
or regular U.S. Mail. You have a period of seven (7) days following your execution of this Agreement to revoke it. If you wish
to revoke the Agreement, you must do so in writing, addressed to the individual in the manner noted in the preceding sentence,
and such revocation must be received by the Company prior to the expiration of the seven-day revocation period. This Agreement
will become effective upon the eighth day after your delivery of this executed Agreement to the Company, provided that you have
not timely revoked this Agreement.

 

    	 - 4 -

     

    

 

12.
Confidentiality. You understand and agree that this Agreement and all of its terms are entirely confidential and
that you shall not disclose, reveal, discuss, publish, or in any way communicate any of the terms, amount or fact of this Agreement
to any other person or entity, including especially the amount of the severance payment. As an exception to this provision, you
may disclose information relating to this Agreement only as necessary (i) to your immediate family members and professional representatives
(including attorneys, accountants and/or tax advisors), who shall be informed of and bound by this confidentiality clause; (ii)
to the extent necessary to enforce or challenge the terms of this Agreement; or (iii) in connection with any charge or complaint
filed by you with the EEOC, NLRB, DOL, SEC, FINRA or any similar federal, state, or local department or agency. You shall promptly
provide written notice of any such order to an authorized officer of the Company.

 

13.
Tax Liability. You agree that you are solely and exclusively liable for any taxable event resulting from the payment
of the sums set out in Section 2 above by the Company to you. You agree to hold harmless and indemnify the Company for any tax
liability, interest, and/or penalties arising out of your failure to pay any taxes the Company is obligated to pay.

 

14.
Acknowledgements. You further agree that each of the following statements is truthful and accurate:

 

(a)
You are of sound mind and body.

 

(b)
You have sufficient education and experience to make choices for yourself that may affect your legal rights.

 

(c)
You are aware that this Agreement has significant legal consequences, and agree that this Agreement is written in a manner that
you can understand.

 

(d)
You have been advised to consult with an attorney of your choice prior to signing this Agreement.

 

(e)
You have decided to sign this Agreement of your own free will, and your decision to sign this Agreement and to resign your employment
has not been unduly influenced or controlled by any mental or emotional impairment or condition or by duress.

 

15.
Miscellaneous.

 

(a)
This Agreement constitutes the full understanding and entire Agreement between you and the Company and supersedes any other agreements
of any kind, whether oral or written, formal or informal, as relates to the subject matter of this Agreement, provided however,
that you remain bound by any continuing obligations to preserve the Company’s business interests, confidential information
and trade secrets, and you remain bound by Section 10 of your Employment Agreement.

 

(b)
In the event your testimony or court appearance is required concerning any litigation the Company is now or may be involved in,
or if in the Company’s opinion, your appearance or testimony would be beneficial to the Company’s position, you agree
to make yourself available to the Company and their counsel, and you agree to use your best efforts to support the Company’s
litigation strategy.

 

    	 - 5 -

     

    

 

16.
This Agreement is expressly conditioned upon your full and continued compliance with all terms of Section 10 of your Employment
Agreement. To the extent that you violate such agreements, you will not earn or be entitled to the Severance and will return any
previously provided Severance.

 

(a)
You represent and acknowledge that in signing this Agreement, you have not relied upon any representation or statement not set
forth in this Agreement. This Agreement may not be amended or modified except by a written instrument signed by the parties.

 

(b)
The failure of a party at any time to require performance of any provision of this Agreement will not affect in any way the party’s
full right to require performance of the same or any other provisions of this Agreement at any time thereafter.

 

(c)
This Agreement will be construed in accordance with and governed by the laws of the State of Louisiana, without giving effect
to the conflict of laws principles of Louisiana law. The parties expressly consent to the exclusive jurisdiction and venue of
any court of competent jurisdiction in Louisiana. The parties expressly waive any claims or defenses of forum non conveniens to
jurisdiction and venue in Louisiana.

 

(d)
Section 5 of this Agreement is integral to its purpose and may not be severed from this Agreement. If any other provision of the
Agreement or compliance by any of the parties with any other provision of this Agreement is found to be unlawful or unenforceable,
such provision will be deemed narrowed to the extent required to make it lawful and enforceable. If such modification is not possible,
such provision will be severed from the Agreement and the remaining provisions will remain fully valid and enforceable to the
maximum extent consistent with applicable law. To the extent any terms of this Agreement are put into question, all provisions
will be interpreted in a manner that would make them consistent with current law.

 

(e)
The headings of the paragraphs of this Agreement are for convenience only and are not binding on any interpretation of this Agreement.

 

(f)
In the event of litigation arising out of this Agreement, the prevailing party will be entitled to an award of its costs and reasonable
attorneys’ fees.

 

(g)
To the extent applicable, it is intended that this Agreement comply with the provisions of Section 409A of the Internal Revenue
Code of 1986, as amended (herein referred to as “Section 409A”). This Agreement will be administered in a manner consistent
with this intent, and any provision that would cause the Agreement to fail to satisfy Section 409A will have no force and effect
until amended to comply with Section 409A. Each separate payment in the series of separate payments will be analyzed separately
for purposes of determining whether such payment is subject to, or exempt from compliance with, the requirements of Section 409A.

 

(h)
This Agreement may be executed in counterparts, and each counterpart, when executed, shall have the effect of a signed original.

 

    	 - 6 -

     

    

 

	EMPLOYEE	 	ONCBIOMUNE
    PHARMACEUTICALS, INC.
	 	 	 
	 /s/
                                         Andrew Kucharchuk

	 	/s/
    Andrew Kucharchuk
	(Signature)	 	(Signature)

 

	Andrew
    Kucharchuk	 	By	Andrew Kucharchuk
	(Print
    Name)	 	 	 
	 	 	 	 
	 	 	Its	Chief Executive
                                         Officer

 

	6/5/20	 	6/5/20
	Date	 	Date

 

Lawsuits,
complaints, or charges (Section 11) are [include name, cause number and court or agency]:

 

 

 

 

 

    	 - 7 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]